The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 12,158.00
Ask: 12,162.00
Change: -90.00 (-0.73%)
Spread: 4.00 (0.033%)
Open: 12,240.00
High: 12,306.00
Low: 12,154.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

The high growth companies that could re-rate in a recession

Wed, 28th Jun 2023 10:55

STOXX 600 up 0.6%, techs among big gainers

*

British SME software maker Sage hits 23-year high

*

Europe stocks head for solid gains in June

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

THE HIGH GROWTH COMPANIES THAT COULD RE-RATE IN A RECESSION (0947 GMT)

The re-rating of high quality and high growth names could be on the horizon in Europe, according to BofA quant strategist Paulina Strzelinska.

While BofA prefers value over growth during the recession phase - given an increased focus on dividend returns - the expected decline in the bond yield nevertheless means high quality names could be positively impacted.

And a lot of those high quality names are also high growth, writes Strzelinska.

BofA provides a list of such names. The list spans companies that are part of the STOXX 600 and have a market cap of at least 500 million euros, and score above 60 on BofA's quality, growth and 'recession' rankings.

The likes of Danish healthcare company Novo Nordisk , French luxury giant Hermes and UK defence company BAE Systems are at the top of the list.

They are followed by France's L'Oreal, Dutch IT company Wolters Kluwer and Italy's Ferrari.

(Lucy Raitano)

TECH TAKES CHARGE IN EUROPE AS NVIDIA RETREATS (0832 GMT)

The STOXX 600 is off to a perky start today, up around 0.6% as it heads for a 0.8% gain this month. Tech stocks, led by Dutch chipmaker ASML and Germany's SAP are among the top weighted gainers on the broader index.

2023's trillion-dollar tech darling Nvidia is down nearly 4% in the premarket after a report in the Wall Street Journal on Tuesday that the U.S. is considering new restrictions on exports of AI chips to China. Nvidia, along with rivals Micron and AMD, are caught in the crossfire between China and Joe Biden's administration right now. Might this mean an edge for their competitors on the other side of the pond?

Amsterdam's AEX is outperforming the broader market, with a gain of nearly 0.7%, as is Frankfurt's DAX, with a gain of 0.8%, thanks to SAP. London's FTSE is around the middle of the pack, with a 0.4% rise on the day, thanks to Astrazeneca, up 0.6% and Sage Group, up 4.1% at a 23-year high after JPMorgan upgraded the software maker, which supplies small and medium-sized companies.

Here's your opening snapshot:

(Amanda Cooper)

EUROPEAN FUTURES RISE (0644 GMT)

European shares were set to open higher on Wednesday taking strength from a positive close on Wall Street following surprisingly upbeat data that showed the U.S. economy is weathering rising rates better than initially thought.

EuroSTOXX50 and FTSE futures were up 0.5% and 0.3% respectively, while in Asia, shares stalled amid lingering concerns over rising interest rates.

Policy makers from Fed Chair Jerome Powell to ECB's Christine Lagarde will have their chance to speak again later in the day at a central banking forum in Portugal.

With little corporate newsflow out there, chipmakers are likely to grab the attention after a WSJ report said Washington was considering new curbs on exports of artificial intelligence chips to China. China's CSI AI index was down over 3% and so Nvidia shares fell by the same magnitude in Frankfurt.

Still on AI, the CEO of business software maker SAP said he saw huge growth potential in generative AI technology.

In M&A, chemicals group Arkema announced a proposed acquisition of a majority stake in South Korean company PI Advanced Materials for 728 million euros ($796.50 million).

BEIJING LEAVES MARKET GUESSING ON YUAN (0558 GMT)

The People's Bank of China seems to like being enigmatic, throwing the market a curve ball as it fixed the yuan weaker against the dollar than many expected. Dealers had thought the firmer fix on Tuesday meant Beijing was signalling it wanted the yuan's fall to slow, or even stop. Now, not so much.

The result has been a drop in the offshore yuan back toward Monday's trough, while the market waits for some clarity on Beijing's intentions.

Sentiment was also not helped by a Wall Street Journal report that Washington is considering new restrictions on exports of artificial intelligence chips to China, which shaved 3% off Nvidia's share price.

The rest of Asia would certainly appreciate a steadier yuan since its fall puts pressure on their currencies to depreciate, to keep their exports competitive with China. Malaysia is set to be the latest to intervene to support its currency, and Japan sounds closer to pulling the trigger every day.

"We are closely watching currency moves with a strong sense of urgency," Japan's top currency diplomat warned, which is about as close as the Ministry of Finance gets to an outright ultimatum.

The last time the MOF intervened, in 2022, they sold a thumping $43 billion of dollars in just two days, so the threat is not to be sniffed at. It was enough to stall the dollar at 144.0 yen, while the euro eased off a 15-year high on the yen.

Still, the market is clearly betting the yen will keep falling unless, and until, the Bank of Japan backs away from its yield curve policy. Bank of Japan chief Ueda speaks later today at the European Central Bank's Sintra jamboree, and will have to justify his super-easy policy while every other central bank on the panel is busy tightening.

It will also be interesting to see if ECB chief Lagarde expands on the idea that firms should stop padding their margins by raising prices - a variation of the argument that this is a profit-price spiral rather than a wage-price spiral.

Once this would have been scorned as a radical view of the far-left fringe, but it's increasingly gaining mainstream acceptance. An OECD study earlier this month argued that profits were a major driver of inflation, especially in the energy and agriculture sectors.

It's tempting to think that, if wages are not the culprit, then central banks might not have to push unemployment up as much as in the past to curb inflation. Yet, Lagarde's conclusion was that policy would need to be tighter for longer so as to hurt demand enough that firms restrained their hunger for profits. That's still a recipe for higher unemployment.

On the bright side, Australian data out Wednesday did show CPI inflation slowing by more than expected to a 13-month low, and that followed a sharp slowdown in Canadian inflation. So maybe there's hope yet.

Key developments that could influence markets on Wednesday:

- ECB President Christine Lagarde, Fed's Jerome Powell, BOJ Governor Kazuo Ueda and Bank of England Governor Andrew Bailey take part in ECB panel in Sintra, Portugal, 1230 GMT

- U.S. data on wholesale and retail inventories, advance goods trade balance

(Wayne Cole)

More News
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more
5 Apr 2024 07:23

AstraZeneca announces positive lung cancer treatment trial results

(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.

Read more
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.